
Online supplement to Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis, *The Journal of Rheumatology*, doi:10.3899/jrheum.150430.

*Supplementary Figure 1.* JIA ACR response rates and inactive disease status (OC data; mITT) over time. JIA: juvenile idiopathic arthritis; ACR: American College of Rheumatology; OC: observed cases; mITT: modified intention to treat.



Online supplement to Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis, *The Journal of Rheumatology*, doi:10.3899/jrheum.150430.

*Supplementary Figure 2.* JIA ACR response rates (LOCF data; mITT) over time. JIA: juvenile idiopathic arthritis; ACR: American College of Rheumatology; LOCF: last observation carried forward; mITT: modified intention to treat.

